254 related articles for article (PubMed ID: 16213344)
21. Dynamics and Clinical Significance of Cytomegalovirus-Specific Neutralizing Antibodies in Kidney Transplant Recipients Treated with T-Cell-Depleting Agents.
Fernández-Ruiz M; García-Ríos E; Redondo N; Rodríguez-Goncer I; Ruiz-Merlo T; Parra P; Sandonis V; López-Medrano F; San Juan R; González E; Polanco N; Andrés A; Navarro D; Aguado JM; Pérez-Romero P
J Infect Dis; 2024 Jun; 229(6):1812-1816. PubMed ID: 37740549
[TBL] [Abstract][Full Text] [Related]
22. A double masked randomised 4-week, placebo-controlled study in the USA, Thailand and Taiwan to compare the efficacy of oral valganciclovir and topical 2% ganciclovir in the treatment of cytomegalovirus anterior uveitis: study protocol.
Takhar JS; Joye AS; Somkijrungroj T; Laovirojjanakul W; Lin CP; Lietman TM; Porco TC; Keenan JD; Gebreegziabher EA; Seitzman GD; Rose-Nussbaumer J; Doan TA; Acharya NR; Gonzales JA
BMJ Open; 2019 Dec; 9(12):e033175. PubMed ID: 31862739
[TBL] [Abstract][Full Text] [Related]
23. A rare case of Cytomegalovirus, Scedosporium apiospermum and Mycobacterium tuberculosis in a renal transplant recipient.
Rathi M; Gundlapalli S; Ramachandran R; Mohindra S; Kaur H; Kumar V; Kohli HS; Gupta KL; Sakhuja V
BMC Infect Dis; 2014 May; 14():259. PubMed ID: 24885965
[TBL] [Abstract][Full Text] [Related]
24. Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients.
Li Y; Pluckrose DM; Patolia R; Arnouk S; Dubrovskaya Y; Papadopoulos J; Jonchhe S
Ann Pharmacother; 2024 May; ():10600280241255110. PubMed ID: 38801191
[TBL] [Abstract][Full Text] [Related]
25. Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients.
Hammer N; Hoessly L; Haidar F; Hirzel C; de Seigneux S; van Delden C; Vogt B; Sidler D; Neofytos D
Transpl Int; 2024; 37():12712. PubMed ID: 38784442
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus antiviral resistance among participants in the phase 3 trial of letermovir vs valganciclovir prophylaxis in kidney transplant recipients.
Strizki JM; Diamond TL; Teal VL; Gilbert CL; Wang W; Stauffer N; Haber B
J Infect Dis; 2024 Jun; ():. PubMed ID: 38853607
[TBL] [Abstract][Full Text] [Related]
27. Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus.
Servais AM; McMullen JS; Bowen R; Kleiboeker SB; Ulloa I; Duncan K; Miles CD
Transpl Infect Dis; 2024 May; ():e14291. PubMed ID: 38708965
[TBL] [Abstract][Full Text] [Related]
28. Congenital and Postnatal Cytomegalovirus: Case Series and State of the Science for Neonatal Providers.
Salemi TF; McLean VR; Jnah AJ
Neonatal Netw; 2024 Apr; 43(2):92-104. PubMed ID: 38599771
[TBL] [Abstract][Full Text] [Related]
29. A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient.
Katada Y; Umemura K; Nakagawa S; Katsube Y; Tsuda M; Tanaka S; Date H; Nagao M; Terada T
J Pharm Health Care Sci; 2024 Jun; 10(1):28. PubMed ID: 38849960
[TBL] [Abstract][Full Text] [Related]
30. Comparison of prophylaxis and preemptive strategy as cytomegalovirus prevention in liver transplant recipients.
Camus C; Poinot M; Pronier C; Rayar M; Neillon AL; Latournerie M; Lagathu G; Revest M
Transpl Infect Dis; 2024 Jun; ():e14282. PubMed ID: 38824435
[TBL] [Abstract][Full Text] [Related]
31. Predictors of Cytomegalovirus Recurrence Following Cessation of Posttransplant Prophylaxis.
Toyoda T; Kurihara C; Kaiho T; Arunachalam A; Lysne J; Thomae BL; Kandula V; Manerikar AJ; Cerier EJ; Tomic R; Budinger GRS; Bharat A
J Surg Res; 2024 May; 299():129-136. PubMed ID: 38754251
[TBL] [Abstract][Full Text] [Related]
32. Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation.
Huh K; Lee SO; Kim J; Lee SJ; Choe PG; Kang JM; Yang J; Sung H; Kim SH; Moon C; Seok H; Shi HJ; Wi YM; Jeong SJ; Park WB; Kim YJ; Kim J; Ahn HJ; Kim NJ; Peck KR; Kim MS; Kim SI
Infect Chemother; 2024 Mar; 56(1):101-121. PubMed ID: 38527780
[TBL] [Abstract][Full Text] [Related]
33. Guillain-Barré syndrome following primary cytomegalovirus infection in a patient with liver transplantation.
Toro J; Gaitán J; Medina T; Reyes S
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38176755
[TBL] [Abstract][Full Text] [Related]
34. Acute Liver Failure Due to Toxoplasmosis After Orthotopic Liver Transplantation.
Baldwin N; Gray M; Patel CR; Al Diffalha S
J Investig Med High Impact Case Rep; 2021; 9():23247096211014691. PubMed ID: 33985363
[TBL] [Abstract][Full Text] [Related]
35. Cytomegalovirus Treatment in Solid Organ Transplantation: An Update on Current Approaches.
Hardinger KL; Brennan DC
Ann Pharmacother; 2024 Mar; ():10600280241237534. PubMed ID: 38501850
[TBL] [Abstract][Full Text] [Related]
36. Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients.
Patil AJ; Sharma A; Kenney MC; Kuppermann BD
Clin Ophthalmol; 2010 Mar; 4():111-9. PubMed ID: 20234777
[TBL] [Abstract][Full Text] [Related]
37. A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients.
Kumar L; Murray-Krezan C; Singh N; Brennan DC; Rakita RM; Dasgupta S; Fisher CE; Limaye AP
Transplant Direct; 2023 Aug; 9(8):e1514. PubMed ID: 37456587
[TBL] [Abstract][Full Text] [Related]
38. High malignancy rate in the absence of viral prophylaxis after kidney transplantation in Sudan.
Elamin S; Ibrahim SS; Mudawi H; Ali SEAM; Abdel-Satir A; Foad AFA
J Nephrol; 2024 Jun; ():. PubMed ID: 38847938
[TBL] [Abstract][Full Text] [Related]
39. Fatal case of macrophage activation syndrome (MAS) in a patient with dermatomyositis and cytomegalovirus (CMV) viraemia.
Lange AV; Kazi S; Chen W; Barnes A
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30061130
[TBL] [Abstract][Full Text] [Related]
40. A practical guide to real-world implementation of pre-emptive therapy for Cytomegalovirus disease prevention in high-risk seronegative liver transplant recipients with seropositive donors.
Heldman MR; Dunn B; Clemens E; Henderson M; Fisher CE; Rakita RM; Kling CE; Limaye AP
Transpl Infect Dis; 2024 Jan; ():e14229. PubMed ID: 38214192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
